newsfilter
← Latest News
GlobeNewswire·

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

Oral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals Poster presentations to include